Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab.

Launched by NOVARTIS PHARMACEUTICALS · Jan 14, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how well a medication called Secukinumab works for people with Hidradenitis Suppurativa (HS), a skin condition that causes painful lumps and sores. The study aims to understand how this treatment affects patients' satisfaction and quality of life in the short term, especially for those living in the Gulf Region. Researchers want to gather real-world feedback from patients who have just started using Secukinumab.

To participate, you need to be at least 18 years old and have a confirmed diagnosis of moderate to severe HS. You should also be starting Secukinumab for the first time. The trial is open to both men and women, and those who have previously used other treatments like antibiotics or surgery may still be eligible. If you join the study, you'll be asked to fill out some questionnaires about your experience with the treatment. This trial is currently recruiting participants, and your involvement could help improve understanding and treatment options for HS.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with a confirmed diagnosis of active moderate to severe HS (Hurley Score 2-3)
• • Male or Female adult patients ≥ 18 years of age at the time of data collection
• • Patient newly initiated on Secukinumab (first dose to coincide within 1 month of the signature of the informed consent)
• • Patients with a diagnosis of HS who are currently using antibiotics/ have undergone surgery or not as part of their routine clinical management are eligible for inclusion.
• • Patients with a diagnosis of HS who have a history of previous treatment with Adalimumab or any other anti-TNF agent as part of their routine clinical management or biologic naïve are eligible for inclusion.
• • Agreed to sign an informed consent to be able to fill in the questionnaires.
• Exclusion Criteria:
• • Patients not fulfilling any of the abovementioned inclusion criteria.
• • Patient's refusal to be included in the study or refusal to sign the informed consent.